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ABSTRACT
Background: Polycystic ovary syndrome (PCOS) is a gynecological endocrine disorder, results in menstrual abnormalities, an-
drogynism and infertility. In the case of women or others animals with PCOS wishing to treat infertility with the aim of becoming 
pregnant, the most commonly used is metformin hydrochloride. Recent studies have analyzed the combination of metformin 
hydrochloride with melatonin in oncological treatment but not to treatment of polycystic ovary syndrome (PCOS). The aim of 
the present study was to analyze the effectiveness of the combination of metformin hydrochloride and melatonin in the treatment 
of PCOS to improve the fertility of rats and your hormonal alterations. 
Materials, Methods & Results: This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the 
Ethics of Animal Experiments of the University of Federal Rural of Pernambuco (Permit Number: 23081.009130/2010). A total 
of 50 albino Wistar rats were used. The animal laboratory of an academic research environment, were randomly separated into 
five groups consisting of 10 females each. After inducing PCOS, the rats were treated with metformin hydrochloride, and/or 
melatonin, and the results compared with standard and ultrasound confirmed. The physiological similarities were confirmed by 
our academic researchers morphological science, and published to the association results of effects syndrome induction through 
constant lighting in reputable magazine recently. This article was analyzed histological of the implantation sites and ovaries, 
and the estradiol and progesterone levels on the seventh day of gestation, and the other rats for monitoring pregnancy and mor-
phological identification of possible fetal abnormalities, weight measurement and quantification of offspring. The rats were 
anaesthetized with intraperitoneal injections of ketamine hydrochloride (80 mg/kg) and xylazine (6 mg/kg) to allow analysis 
of the reproductive organs. Main outcome measures: The study included histopathology, histochemical and quantitative (of the 
implantation sites) tests, ultrasound analysis, weight benchmarking and ovarian histology tests, as well as comparison of serum 
estradiol and progesterone levels, and the morphological assessment of offspring. Results paper shows pharmacological treat-
ment reduced the time needed for pregnancy, increased the plasma progesterone levels, the number and weight of offspring, and 
reduced plasma estrogen levels and collagen fiber grade, improving blastocyst-endometrium interaction and fetal development.
Discussion: Our team of researchers confirmed in a previous paper; in addition, the main experimental model used in research about 
PCOS in recent years, and considered appropriate combination of the drugs caused a physiological reaction similar to responses 
identified in healthy rats without induction of the POS control group. However, the clinical and physiological effectiveness of 
the combination should be further explored, especially with respect to the possible side effects on offspring. The treatment with 
a combination of metformin hydrochloride and melatonin was more effective against hormonal alterations produced by PCOS, 
allowing a normalization of biochemical parameters during pregnancy, than monotherapeutic treatment with these drugs. In 
conclusion, proposed drug combination is a viable option to treatment of polycystic ovary syndrome and improved fetal develop-
ment. This article allows suggest that further research should be conducted to examine effects associated with these drugs in the 
treatment of diseases of the female reproductive system experimentally. Only such treatment later in animals and humans suggest. 
Keywords: polycystic ovaries, metformin, melatonin, reproduction, estradiol, progesterone.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) character-
ized by amenorrhea, hyperandrogenism and/or hyper-
androgenemia and follicular cysts, characterizing this 
syndrome as one of the main causes of female infertil-
ity [12,14,15,26,41,]. The treatment of PCOS varies 
according to the symptoms of the patient and usually 
takes the form of the administering of antiandrogens 
and antidiabetic agents such as metformin, often in 
combination with contraceptive hormones. Metformin 
is the most widely used drug in clinical cases of the 
disorder among patients seeking treatment of infertility, 
and considered safer than the other treatments [13,18].
Some authors have associated the pathogenesis 
of diseases that cause infertility, such as PCOS, endo-
metriosis and other disorders of the female reproduc-
tive system, to oxidative stress. Literature reveals that 
melatonin is a broad-spectrum antioxidant produced by 
the pineal gland with a principally hormonal function, 
controlling cyclicity and reproductive functions. Its 
levels tend to increase during pregnancy, demonstrating 
its importance to gestational physiology [2,5,29,33,34]. 
The combined of metformin and melatonin 
therapy had better results for levels of lipid peroxida-
tion (LPO) compared with monotherapeutic use of these 
drugs in rats [1,17,37]. However, there are no reports 
in literature on the combination of metformin and 
melatonin for the treatment of ovarian polycystosis and 
its viability in improving implantation [16,30,31,38]. 
Therefore, the present study tested the hypothesis that 
melatonin can enhance the performance of metformin in 
experimental models induced in the polycystic ovaries, 
by constant illumination, enhancing conceptive viability. 
MATERIALS AND METHODS
Installation of bioassay
The experiment was performed in the Histol-
ogy Laboratory of the Department of Animal Morphol-
ogy and Physiology of the Universidad Federal Rural 
of Pernambuco. A total of 50 albino (Rattus norvegicus 
albinus) Wistar rats, aged 90 days and weighing ap-
proximately 200 ± 30 g, were used. The rats were taken 
from the biotery of the department.
The rats kept in cages and supplied with food 
and water ad libitum. Temperature of 22 ± 1oC and 
under artificial lighting, establishing a photoperiod of 
12 h of light and 12 h of darkness, with the light period 
being from 06:00 to 18:00.
After an adjustment period, vaginal smears 
were collected to determine the estrous cycle. Female 
rats who had undergone three regular estrous cycles 
were randomly separated into five groups, each consist-
ing of 10 animals. Five for the purposes of histologi-
cal analysis of the implantation sites and ovaries, and 
the plasma estradiol and progesterone levels on the 
seventh day of gestation, and the other rats for moni-
toring pregnancy and morphological identification of 
possible fetal abnormalities, weight measurement and 
quantification of offspring.
Group I - rats without ovarian polycystosis 
were kept in a 12/12 h light/dark cycle for 100 days 
and then mated (control);
Group II - rats with induced ovarian polycys-
tosis and then mated (PCOS + Placebo);
Group III - rats with induced ovarian poly-
cystosis treated with melatonin for 20 days and then 
mated (PCOS + Mel);
Group IV – rats with induced ovarian poly-
cystosis treated with metformin for 20 days and then 
mated (PCOS + Met);
Group V - rats with induced ovarian polycysto-
sis treated with melatonin and metformin for 20 days 
and then mated (PCOS + Mel + Met).
Induction of Polycystic Ovary Syndrome
For the induction of PCOS, the rats of groups 
II, III, IV and V subjected to constant light stimulation, 
achieved using a wooden box with an area of 0.5 m³, with 
slits for ventilation, containing two fluorescent PHIL-
LIPS 40W lamps, which provided sufficient brightness 
of around 400 lux. These lamps remained continuously 
lit for a period of 100 days, enough time for the develop-
ment of the clinical features of PCOS [20,35]. The pres-
ence of PCOS was confirmed by ultrasound. After the 
period of continuous lighting change androgenic hormone 
function, contributes to the induction of PCO disease of 
female rats. Irregularity androgens result from a reduc-
tion in sensitivities to estradiol and progesterone that are 
involved with GnRH release from hypothalamic centers. 
Consistent hormonal changes have been reported among 
various studies utilizing constant light rat PCO models. 
Compared to control values, plasma luteinizing hormone 
levels were normal, follicle-stimulating hormone and 
estradiol levels were elevated. Thus, the constant light 
rat model presents absence of corpus luteum, which is an 
indication of chronic anovulation, electron microscopic 
studies of PCO ovaries showed thickening in the tunica 
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albuginea and abnormalities of the stroma and of granu-
losa and theca cells relative to control [27].
Ultrasound of ovaries 
The analysis of ultrasounds was performed in 
the Department of Veterinary Medicine of UFRPE. The 
images were in double blind obtained before and after 
the treatment of rats, by using the ESAOTE / MyLab 
GOLD™ 30-ultrasound machine with a 10MHz fre-
quency linear transducer. The rats were intramuscularly 
anesthetized with ketamine hydrochloride (80 mg/kg) 
and xylazine (6 mg/kg) and manually immobilized. The 
abdomens of the rats were moistened with 70% alcohol 
to enable ultrasounds to be performed, and the position 
and size of the ovaries was identified, taking as a refer-
ence the position of the kidneys and the evaluating the 
echotexture and echogenicity of the organ.
Treatment with Metformin Hydrochloride
Metformin hydrochloride (Glifage®)¹ was 
administered by gavage at a dose of 50 mg/100 g b.w. 
diluted in 0.5 mL of distilled water for twenty consecu-
tive days. The dose of metformin administered was 
equivalent to that used in the treatment of women with 
PCOS, that is 500 mg/day, and that keep the pharma-
codynamics [10,28].
Treatment with Melatonin
After the rats were weighed, rats from group III 
and group V were treated with melatonin in accordance 
with the methodology described by Prata-Lima et al. 
[25]. (Melatonin)² was administered at a dose of 200 
μg/100 g b.w. by subcutaneous injections in the eve-
ning (18:00) for twenty consecutive days. According 
to Drobnik et al. [9], doses higher than 60 and below 
300 μg/100 g b.w. expressed an equivalent effect to 
endogenously secreted pineal indoleamine. The mela-
tonin dissolved in ethanol (0.02 mL) and diluted with 
0.2 mL of sodium chloride (0.9% NaCl).
Mating of animals and confirmation of copulation
After treatment the females placed were for 
mating daily, in the evening (18:00), at a ratio of one 
male to two females. Cervical cytology was performed 
to confirm and monitor the mating receptivity of the 
females, using the presence of spermatozoa in vaginal 
smears as a parameter. This was considered as the first 
day of gestation. Rods fitted at the ends with cotton balls 
soaked in saline were used to collect smears. Immedi-
ately after sample collection, the cells were transferred 
to histological slides through rotational movements of 
the rod. These slides were immediately immersed in a 
solution of ether alcohol in equal parts, and were then 
stained using the Harris-Shorr method. Recorded the 
time that the females of all groups needed to mate.
Blood collection for determination of plasma estradiol 
and progesterone levels
The rats were immobilized in wooden boxes 
and blood was collected by puncturing the lateral tail 
vein with a catheter (24G) on the seventh day of gesta-
tion. After centrifugation, chilled plasmas were placed 
in 1.5 mL microcentrifuge tubes and frozen at -20°C 
until dosage [11,36]. The plasma levels of estradiol and 
progesterone were assayed using the Enzyme Linked 
Immunosorbet Assay (ELISA) using commercial kits 
(ADI 900-100 lot n.: 05121109) and (ADI 900-011 
lot n.: 10191116B) respectively, both manufactured 
by Enzo LifeSciencePRO. 
Histology and morphometry of uterus collagen fibers
On the seventh day of gestation, five females from 
each group were anesthetized intramuscularly with ket-
amine hydrochloride (80 mg/kg) and xylazine (6 mg/kg). 
The uterine horns containing the implantation sites and 
the ovaries were collected. The ovaries were weighed on 
an analytical scale and the implantation sites were quanti-
fied with the aid of a magnifying glass. All samples were 
then immediately immersed in 10% buffered formalin. 
The samples were subsequently processed for inclusion 
in paraffin and the sections underwent hematoxylin-eosin 
(HE) staining. These were examined using an Olympus 
BX-49 light microscope and photographed with an Olym-
pus BX-50 photomicroscope. For morphometric, the 
implantation sites were stained with sirius-red/fast-green 
(RG). Gimp2.6 software (GNU Image Manipulation 
Program, UNIX platforms) used to quantify the changes 
in the pixels of the stained material. The results recorded 
underwent statistical testing, and a comparison chart of 
the groups was created.
Monitoring of copulation
The rats were monitored to determine time of 
mating. When mating was confirmed they were weighed 
daily until the end of pregnancy. During this period 
number of abortions and the weight loss of the rats was 
monitored. After birth, the offspring weigh, were quanti-
fied and analyzed macroscopically for the presence of 
visible malformations in the head, trunk or limbs.
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Statistical analysis
Nonparametric Kruskal-Wallis analysis was 
used. Where necessary, means were compared using 




The statistical analysis of the ovarian dimen-
sions revealed by the ultrasounds showed a significant 
increase in the dimensions of the ovaries of the females 
of all groups induced with PCOS. However, after treat-
ment there was a significant reduction in the ovaries 
size in the female treated with melatonin, metformin 
and a combination of these drugs (Table 1). 
Weight of the female rats during treatment and pregnancy
There was no statistically significant difference 
in the weight of the rats during treatment, however, 
during pregnancy the rats from the group PCOS + 
Placebo displayed reduced weight gain. This was the 
only experimental group to differ from the control 
group (in which PCOS was not induced) and PCOS 
+ Mel (in which PCOS was induced and treated with 
melatonin). In other words, all the groups treated with 
single drugs or combinations of drugs had improved 
gestational weight gain balance (Table 1).
Analysis of the time required for copulation and fertility
The number of days required for confirmation 
of pregnant, was significantly higher in the PCOS + 
Placebo group. Furthermore, only 30% of the females 
in this group enabled copulation. Replacement of the 
placebo with melatonin did not result in significant 
differences in relation to the control group and the 
PCOS + Placebo group. On the other hand, treatment 
with metformin or with a metformin and melatonin 
combination significantly reduced of the confirmation 
of pregnant compared to the PCOS + Placebo group 
(Figure 1A). The PCOS + Placebo group presented 
a statistically significant reduction in the number of 
implantation sites on the seventh day of gestation, and 
offspring (Figure 1B). On the seventh day of gestation, 
none of the experimental groups displayed evidence 
of abortion reabsorption into the uterine horns. There 
were no stillbirths, alteration in number of offspring 
(Figure 1C) or morphological identification of malfor-
mations, but it has been found a statistically significant 
reduction in the weight of offspring from the PCOS + 
Placebo group (Figure 1D).
Ovarian weight, estradiol and progesterone levels and 
immunohistochemistry uterus
The ovarian weights of the females of all group 
in treatment with metformin hydrochloride, melatonin 
or combination of both drug, reduced the weight of 
the ovaries. None of the treatments reduced the values 
to resemble the group uninduced to PCOS. Of these 
groups, the rats receiving only metformin hydrochlo-
ride showed values similar to the group that had PCOS 
+ Placebo, these last groups showed the highest values 
measured weights of ovaries (Figure 2A).
Levels of estradiol in the plasma of rats in which 
polycystic ovary syndrome was induced, and which 
received only a placebo were statistically higher than 
those observed in other groups. The PCOS + Mel, PCOS 
+ Met and PCOS + Met + Mel had the highest averages 
in relation to the control PCOS + Placebo groups, with 
these being more significant in the latter group. In turn, 
the PCOS + Placebo group had lower levels of pro-
gesterone and was statistically different from the other 
experimental groups (Figures 2B and 2C).
In terms of the presence of collagen fibers, 
the group induced with PCOS and treated only with a 
placebo revealed greater intensity, identified through 
picro-sirius and fast green dye, compared to the other 
groups. The groups that were treated with melatonin or 
metformin had statistically significant collagen mark-
ing when compared to the PCOS + Placebo group. 
However, the combination of metformin and melato-
nin produced a greater reduction in collagen labeling 
compared to PCOS + Placebo, but was not statistically 
different from the control group (Figure 2D).
Histological analysis 
The implantation sites of the female rats in 
all the experimental groups were well-preserved and 
fully inserted in the uterus wall (Figures 3A-3E). The 
ovaries of the control rats revealed the presence of 
corpus luteum with well-preserved luteal cells, and the 
presence of follicles at different stages of development 
(Figure 4A). In the PCOS + Placebo group were many 
atresics follicles with a discreet presence of corpus 
luteum (Figure 4B). The experimental groups that were 
treated with metformin or a combination of metformin 
and melatonin had histologic features similar to the 
control group (Figures 4C-4E).
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Table 1. Mean and standard deviation of experimental data of rats subjected to the experimental model of polycystic ovary syndrome.
Grupo Control PCOS + Placebo PCOS + Mel PCOS + Met PCOS + Mel + Met Fp
US1(cm²) 0,08 ± 0,01a 0,46 ± 0,10b 0,57 ± 0,12b 0,65 ± 0,17b 0,52 ± 0,13b 12,530,001
US2(cm²) 0,11 ± 0,02a 0,36 ± 0,04b 0,24 ± 0,05a 0,26 ± 0,19a 0,27 ± 0,86a 22,940,001
WT(g) 228,80 ± 22,12a 240,76 ± 17,67a 229,80 ± 17,56a 226,86 ± 12,65a 226,86 ± 12,65a 0,40750,8011
WP(g) 245,88 ± 14,16a 255,17 ± 20,21a 242,91 ± 15,75a 237,22 ± 27,74a 244,37 ± 24,75a 0,47240,7554
WGP(g) 122,6 ± 19,56a 62,8 ± 15,75b 110,8 ± 10,43a 98,6 ± 15,33a 98,2 ± 11,56a 3,93680,0162
Ovarian diameter measured by ultrasound after induction of polycystic ovary syndrome (US1), measurement of the diameter of the ovary after treatment 
(US2), weight of rats during treatment (WT), weight of rats during pregnancy (WP) and weight gain during pregnancy (WGP). Means followed by the 
same letter in the parameters analyzed did not differ significantly, according to the Wilcoxon-Mann-Whitney test (P > 0.05).
Figure 1. Note significant increase in the time required for copulation (A) 
and reduction in the number of implantation sites (B), and of number (C) 
and weight of the offspring (D) in PCOS + placebo group compared to 
the other experimental groups. Means followed by the same letter in the 
parameters analyzed did not differ significantly, according to the Wilcoxon-
Mann-Whitney test (P < 0.05).
Figure 2. Note values of ovarian weight (A) and estradiol levels (B) similar 
to the control after treatment with Mel, Met and Mel + Met. (C) Check 
significant increase in progesterone levels, compared to control, being more 
significant in the group PCOS Mel + Met. (D) Reduction in content of col-
lagen fibers after treatment with Mel, Met e Mel + Met, when compared 
with group PCOS + placebo. In treatment with combination of drugs the 
content of collagen fibers was similar to Group control. Means followed 
by the same letter in the parameters analyzed did not differ significantly, 
according to the Wilcoxon-Mann-Whitney test (P < 0.05).
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Figure 3. Sites of implantation. (A) control, (B) PCOS + Placebo, 
(C) PCOS + Mel, (D) PCOS + Met and (E) PCOS + Mel + Met. H.E. 
[Bars = 100 μm].
Figure 4. Ovaries. (A) control, (B) PCOS + Placebo, (C) PCOS + Mel, 
(D) PCOS + Met and (E) PCOS + Mel + Met. H.E. [Bars = 200 μm]. cl: 
corpus luteum; f: follicles; af: atresic follicles.
DISCUSSION
Our team of scientists has been working for 
many years with the female reproductive system and 
after long-term research, recently published on the 
physiological similarities of symptoms of polycystic 
ovary syndrome compared to the experimental model. 
This research team found that there is benefit in linking 
drug in the treatment of polycystic ovary syndrome. 
Female rats from the PCOS + Placebo group had lower 
weight gain during pregnancy, while those animals 
treated with melatonin, had weight gains similar to 
those of the control group. Additionally, there was a 
reduction in the number of implantation sites observed 
in rats from the PCOS + Placebo group, resulting 
in a reduced number of offspring. There was also a 
histhochemical increase in collagen content in the 
uterine horns, which may have hindered blastocyst-
endometrial interaction. On the other hand, rats that 
received treatment with either a combination of drugs 
or a single drug had a similar number of implantation 
sites and offspring to the control group. With respect 
to collagen fiber, content only the PCOS + Mel + Met 
group had similar values to the control group, while 
the PCOS + Mel and PCOS + Met groups revealed a 
significant reduction in collagen fiber content in rela-
tion to the PCOS + Placebo group. Endocrinologically, 
plasma progesterone levels were higher in the groups 
in which rats were treated with a combination of 
drugs or a single drug, with the difference being more 
statistically significant where treatment involved a 
combination of drugs, suggesting that such treatment 
has a synergistic effect on the release of progester-
one. This may have occurred due to the function of 
melatonin as a protector of the granulosa cells, which 
are precursors of the corpus luteal as a producer of 
progesterone, when 100 μg/100g animal body weight 
was administered orally to rats for 60 days [32]. There 
was also an antioxidant effect on human follicle cell 
incubation experiments, and regulating progesterone 
receptors at a concentration of 100 mg/mL [6]. In the 
same way metformin administered in a dose of 500 
mg/day for 35 days resulted in an increase in plasma 
progesterone levels in 90% of women undergoing treat-
ment of PCOS, who quickly began to ovulate again 
[20,23]. In cell culture it was shown that metformin 
leads to the restoration of progesterone and improves 
its genetic markers [40]. This explains the occurrence 
of increased levels of progesterone when treated with 
melatonin combined with other drugs is used, proving 
the synergy of the effects of such treatment.
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Estrogen levels in the PCOS + Placebo group 
were high. This was most likely due to the physiologi-
cal response to this syndrome leading to irregularities 
in the production of the hormone, or because non-
treatment of the syndrome may lead to conversion 
of androgens to estrogen hormones. In some cases, 
endometrial cancer can occur because of excessive 
estrogen, as well as leading to increased oxidative 
stress and consequently, increased activation of cyto-
kines in the body or fibroids in the uterus [19,22]. This 
growth hormone also explains the increase in collagen 
fiber content in rats in the PCOS + Placebo groups, 
as according to Batista et al. [4], fibroblasts, the cells 
responsible for collagen synthesis, are estrogen depen-
dent, and increase their synthesis in situations with high 
estrogen levels. Therefore, due to the return of plasma 
estrogen levels to values similar to the control group, 
in females treated with a combination of drugs or a 
single drug, there was a significant reduction in col-
lagen fiber content, mainly in the PCOS + Mel + Met 
group. In addition, the restoration of estrogen levels 
to values similar to the control group reduced the time 
required for pregnancy when compared to the PCOS 
+ Placebo group, which had a longer period. This can 
be explained by the fact that when rats are subjected to 
constant illumination for the induction of PCOS, there 
is a break in estrous cyclicity, establishing an estrous 
framework with high estrogen levels, necessitating 
a longer period for the resumption of cyclicity after 
interruption by light stimulus [27].
Treatment with drugs associated or not, led 
to a reduction in ovarian size and also to reduce the 
weight of the ovaries, although they have not reached 
similar values to those without PCOS. Among the treat-
ments, only the rats receiving metformin hydrochlo-
ride remained with the average weight similar to the 
weight of the ovaries of rats induced the PCOS group 
that received only placebo. Probably these findings 
are related to the activities indirectly the metformin 
hydrochloride in ovarian cells. This is associated with 
the ability of melatonin to regulate the hypothalamic 
axis, inhibiting the release of hormones such as follicle 
stimulating hormone, which aids in the reduction of 
cysts. Additionally, has anti-inflammatory and anti-
toxic effects, acts against free radicals, and reduces 
cytokines that are part of the activation process of the 
synthesis by fibroblasts [24,25]. Another function of 
melatonin is to regulate the gonadotropin releasing 
hormone (GnRH) through its MT1 and MT2 recep-
tors, which are members of receptors coupled to the G 
7-transmembrane protein in the granulosa luteal cells, 
that inhibit GnRH receptor expression and preserve the 
corpus lutea, and consequently increase progesterone 
production [21,39]. Thus, the luteal cells remain ac-
tive and help to reduce ovarian weight by decreasing 
the content of ovarian polycystic. Although normal 
reproductive functions are restored, ovarian weight 
most likely increases because the kinetics of metformin 
hydrochloride characteristically act directly on cells 
that secrete ovarian theca. Their modulation involves 
activation of the AMPK (adenosine monophosphate-
activated protein kinase) enzyme, which is an enzyme 
that acts on the ovaries, promoting the inhibition of 
CYP17 activity (enzyme 17a hydroxylase-17, 20-ly-
ase). CYP17 is responsible for reducing the conversion 
of androgens and stabilizing the production of steroid 
hormones, in addition to promoting increased proges-
terone production [3,7,8]. The benefits of membership 
of the drugs were also evident in reducing oxidative 
stress control and molecular proinflammation factors, 
as reported by some scientific letters [16,17]. Thus, 
there was improvement that is more significant in the 
group with PCOS and treated with melatonin and the 
group treated with the combination of drugs, showing 
that the combination of these drugs improves the physi-
ological state of the rats, when compared to rats of the 
group that received only hydrochloride metformin.
CONCLUSION
Concluded that the proposed drug combination 
is a viable option for the recovery of cyclicity, reduc-
tion of plasma estrogen levels to normal, leading to a 
reduction in bonding fiber content in the endometrium, 
and promoting a significant increase in progesterone, 
making implantation possible. In addition, reduc-
ing time required for pregnancy, thereby improving 
blastocyst-endometrium interaction and resulting in 
improved fetal development.
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